AbbVie Inc. (ABBV)
NYSE: ABBV · Real-Time Price · USD
225.11
-2.59 (-1.14%)
At close: Dec 1, 2025, 4:00 PM EST
224.77
-0.34 (-0.15%)
After-hours: Dec 1, 2025, 7:24 PM EST
AbbVie Revenue
AbbVie had revenue of $15.78B in the quarter ending September 30, 2025, with 9.10% growth. This brings the company's revenue in the last twelve months to $59.64B, up 7.40% year-over-year. In the year 2024, AbbVie had annual revenue of $56.33B with 3.71% growth.
Revenue (ttm)
$59.64B
Revenue Growth
+7.40%
P/S Ratio
6.68
Revenue / Employee
$1,084,436
Employees
55,000
Market Cap
397.86B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 56.33B | 2.02B | 3.71% |
| Dec 31, 2023 | 54.32B | -3.74B | -6.44% |
| Dec 31, 2022 | 58.05B | 1.86B | 3.30% |
| Dec 31, 2021 | 56.20B | 10.39B | 22.69% |
| Dec 31, 2020 | 45.80B | 12.54B | 37.69% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
| Abbott Laboratories | 43.84B |
ABBV News
- 13 hours ago - AbbVie: Increased Outlook For 2025 And Expansions Merit Continued "Strong Buy" Rating - Seeking Alpha
- 2 days ago - 3 High-Yielding Dividend Growth Stocks That Can Generate Passive Income for Your Portfolio for Years - The Motley Fool
- 2 days ago - Best Dividend Aristocrats For December 2025 - Seeking Alpha
- 3 days ago - SKYRIZI® (risankizumab) Receives Positive Reimbursement Recommendation by Canada's Drug Agency for Ulcerative Colitis and AbbVie Concludes Letter of Intent with the pan-Canadian Pharmaceutical Alliance - GlobeNewsWire
- 3 days ago - 8 Dividend Stocks Every Investor Should Consider - The Motley Fool
- 6 days ago - AbbVie and adMare BioInnovations Foster Life Sciences Innovation with the Launch of the AbbVie Biotech Innovators Award in Quebec - GlobeNewsWire
- 7 days ago - AbbVie to Present at the Piper Sandler 37th Annual Healthcare Conference - PRNewsWire
- 7 days ago - 5 Dividend Stocks to Hold for the Next 10 Years - The Motley Fool